Top 20 Genetic Testing & Genomics Providers 2023

This report forms part of the Ranking News Healthcare Ranking series, which evaluates hospitals, medical institutions, pharmaceutical organizations, medical technology companies, diagnostics providers, laboratories, precision medicine platforms, and healthcare systems across global healthcare markets.

Genetic testing and genomics providers have become central to the transformation of modern medicine. Their services support hereditary risk assessment, rare disease diagnosis, reproductive health, oncology treatment selection, pharmacogenomics, organ transplant monitoring, population screening, and precision medicine. As healthcare moves from symptom-based treatment toward molecularly informed care, genomics providers increasingly serve as core infrastructure for diagnosis, prevention, and therapy selection.

Unlike traditional clinical laboratories focused primarily on routine blood testing, genetic testing and genomics providers operate platforms that combine sequencing technology, molecular biology, variant interpretation, bioinformatics, genetic counseling, clinical reporting, data infrastructure, and regulatory compliance. Their institutional relevance is determined not only by test volume, but also by clinical utility, interpretive quality, data scale, physician adoption, reimbursement access, and integration with healthcare systems.

The sector includes several distinct provider types. Large laboratory networks offer broad genetic testing menus to physicians and health systems. Specialist companies focus on hereditary cancer, reproductive genetics, rare disease sequencing, liquid biopsy, oncology profiling, or population genomics. Technology-driven genomics companies combine sequencing, artificial intelligence, and clinical data platforms to support precision medicine and life sciences research.

This ranking identifies genetic testing and genomics providers whose platforms demonstrate sustained relevance across clinical genetics, molecular diagnostics, oncology genomics, reproductive health, rare disease diagnosis, population screening, and precision medicine. Rather than focusing solely on sequencing volume or technology ownership, the objective is to recognize organizations whose genomics platforms play a meaningful role within the global healthcare ecosystem.

Market Overview

The genetic testing and genomics provider sector has expanded rapidly as sequencing costs have declined, clinical guidelines increasingly incorporate molecular testing, and healthcare systems adopt precision medicine across oncology, reproductive health, rare disease, cardiology, neurology, and pharmacogenomics. Genetic testing is no longer confined to research laboratories; it is now part of mainstream clinical care.

Large diagnostic companies such as Labcorp and Quest Diagnostics have integrated genetics into broad clinical laboratory platforms. Labcorp describes its genetic testing offering as a comprehensive menu supported by access to genetic counselors, while Quest Diagnostics highlights a genetics portfolio designed to support precision medicine and offers more than 700 orderable genetic tests through its genomic infrastructure services.

Oncology genomics remains one of the most commercially and clinically important segments. Foundation Medicine reports more than 1.5 million comprehensive genomic profiling reports delivered, while Guardant Health focuses on cell-free DNA and liquid biopsy testing for early and advanced cancer applications. These platforms are increasingly relevant because targeted therapies, immunotherapies, resistance monitoring, and clinical trial matching depend on molecular information.

Reproductive genetics and hereditary risk testing remain major markets. Natera describes itself as focused on cell-free DNA testing in oncology, women’s health, and organ health, while Myriad Genetics offers hereditary cancer, prenatal, oncology, and mental health genetic testing services. Ambry Genetics and GeneDx represent another important segment: hereditary cancer, rare disease, exome sequencing, genome sequencing, and inherited condition testing.

The sector also includes sequencing technology and informatics companies that support clinical genomics infrastructure. Illumina provides sequencing and array technologies used across life science research, translational genomics, consumer genomics, and molecular diagnostics, while Tempus positions itself around AI-powered precision medicine and large-scale clinical and molecular data.

Industry Trend — 2023

The genetic testing and genomics industry in 2023 is shaped by five major trends: clinical mainstreaming, oncology precision medicine, whole exome and whole genome sequencing, population genomics, and data-driven interpretation.

First, genetic testing is becoming more integrated into routine care. Physicians increasingly use genetic information to assess inherited cancer risk, diagnose rare diseases, guide reproductive decisions, select cancer therapies, identify pharmacogenomic risks, and support preventive care. Providers with broad physician access, payer coverage, genetic counseling, and reliable reporting are better positioned for sustained clinical adoption.

Second, oncology continues to drive demand for comprehensive genomic profiling and liquid biopsy. Foundation Medicine’s tumor profiling database, Guardant’s blood-based comprehensive genomic profiling, Tempus’ oncology-focused clinical and molecular data platform, and NeoGenomics’ cancer diagnostics platform all reflect the central role of genomics in modern cancer care.

Third, whole exome and whole genome sequencing are becoming more important in rare disease and pediatric diagnosis. GeneDx emphasizes whole exome and genome sequencing for rare and inherited conditions, while Fulgent Genetics highlights whole genome sequencing, rare disease testing, and broad single-gene testing capabilities. As interpretation improves, comprehensive sequencing is increasingly used earlier in the diagnostic journey rather than as a last resort.

Fourth, population genomics is moving from research into implementation. Color Health describes population genomics capabilities for screening broad populations for CDC Tier 1 genomic conditions, including recruitment, return of results, and genetic counseling. This model is important for health systems, employers, and public health programs seeking scalable preventive genetics.

Fifth, data scale and interpretation quality are becoming strategic assets. Genomics providers increasingly compete not only on sequencing cost but also on variant databases, phenotype-linked data, clinical evidence, reporting clarity, genetic counseling, AI-supported interpretation, and links to clinical action. In a field where many variants are uncertain or context-dependent, interpretive infrastructure is often as important as the sequencing platform itself.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, organizations considered for this ranking were evaluated based on the following eligibility conditions:

• Operates primarily as a genetic testing provider, clinical genomics company, molecular diagnostics platform, sequencing services provider, or precision medicine genomics platform
• Provides services such as hereditary risk testing, reproductive genetics, oncology genomic profiling, rare disease sequencing, pharmacogenomics, population genomics, liquid biopsy, or clinical whole exome / whole genome sequencing
• Maintains meaningful institutional scale through clinical laboratory operations, physician networks, payer access, international reach, hospital partnerships, or large clinical data platforms
• Demonstrates relevance in clinical decision-making, precision medicine, preventive care, oncology, reproductive health, rare disease diagnosis, or population screening
• Maintains systems for laboratory quality, clinical interpretation, bioinformatics, data security, genetic counseling, regulatory compliance, and medical reporting

Pure research sequencing centers, ancestry-only consumer testing brands without substantial clinical infrastructure, software-only bioinformatics vendors, and medical device manufacturers without meaningful clinical testing or genomics service platforms were generally excluded.

Methodology — Ranking Factors

Organizations included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term financial performance alone. Key factors considered include:

• Scale and clinical reach of the genetic testing platform
• Breadth of hereditary, reproductive, oncology, rare disease, and pharmacogenomic testing
• Strength of sequencing, molecular biology, bioinformatics, and variant interpretation capabilities
• Integration with physicians, health systems, payers, genetic counselors, and life sciences partners
• Clinical utility, evidence base, reimbursement access, and reporting quality
• Role in precision oncology, reproductive health, population genomics, or rare disease diagnosis
• Data infrastructure, AI capability, and longitudinal clinical-molecular datasets
• Institutional stability, brand reputation, and long-term platform resilience

The objective of the ranking is to identify genetic testing and genomics providers whose platforms maintain sustained relevance within the global healthcare ecosystem.

The Healthcare Ranking Top 20 Genetic Testing & Genomics Providers 2023 ranking evaluates organizations providing clinical genetic testing, genomic profiling, sequencing services, molecular diagnostics, and precision medicine data platforms across global healthcare markets.

The ranking universe consisted of approximately 120 genetic testing and genomics providers globally, from which 20 organizations were selected for inclusion.

Tier classifications reflect relative institutional positioning within the genetic testing and genomics provider segment and do not represent clinical outcome rankings, patient recommendations, or investment recommendations.

---

Tier I — Leading Global Genetic Testing & Genomics Providers

Labcorp / Invitae

• Headquarters: Burlington, United States
• Founded: 1978
• Core focus: Clinical genetic testing, hereditary disease, reproductive genetics, oncology, broad laboratory access

Labcorp is one of the most important global providers of clinical genetic testing, supported by its broader laboratory network, physician access, payer relationships, and acquisition of Invitae. The combination gives Labcorp a major platform across hereditary cancer, reproductive genetics, rare disease, pharmacogenomics, oncology, and general clinical genetics.

Labcorp’s strength lies in its ability to integrate genetic testing into mainstream clinical care. The company highlights a comprehensive genetic test menu and access to genetic counselors, which is important because genetic testing often requires interpretation, family-history review, risk communication, and follow-up decision support. Labcorp also states that Invitae and Labcorp together offer advanced genetic testing services that can be integrated into medical practices.

The platform is especially relevant because genetic testing adoption depends heavily on ordering convenience, insurance access, physician trust, and sample logistics. Labcorp’s national and international laboratory infrastructure gives it advantages that smaller specialty genomics providers may find difficult to replicate.

Its combination of broad test access, clinical laboratory scale, genetic counseling support, Invitae’s specialist genetics capabilities, and established provider relationships supports its position as a leading genetic testing and genomics provider in 2023.

Illumina Clinical Genomics

• Headquarters: San Diego, United States
• Founded: 1998
• Core focus: Sequencing technology, clinical genomics infrastructure, whole-genome sequencing

Illumina is one of the foundational companies in modern genomics and remains central to the infrastructure of sequencing-based medicine. While best known as a sequencing technology company, Illumina’s role in clinical genomics is highly significant because many laboratories, hospitals, research institutions, and molecular diagnostics companies rely on sequencing platforms and informatics workflows derived from Illumina technology.

Illumina describes its sequencing and array technologies as supporting life science research, translational and consumer genomics, and molecular diagnostics. Its clinical materials also note that the MiSeqDx system was the first FDA-cleared in vitro diagnostic next-generation sequencing system, underscoring the company’s relevance to regulated clinical genomics.

The company’s strength lies in its enabling role. Illumina does not need to dominate every downstream testing category to remain essential; its platforms support clinical sequencing, oncology profiling, rare disease testing, reproductive genetics, infectious disease genomics, and population genomics programs across the industry.

Illumina’s sequencing leadership, clinical laboratory capabilities, informatics ecosystem, and global footprint support its position among the leading genetic testing and genomics providers, particularly as the industry continues to move toward whole-genome and high-throughput molecular medicine.

Natera

• Headquarters: Austin, United States
• Founded: 2004
• Core focus: Cell-free DNA testing, reproductive genetics, oncology, organ health

Natera is one of the most important specialist companies in clinical cell-free DNA testing. The company focuses on women’s health, oncology, and organ health, using cell-free DNA technologies to support noninvasive prenatal testing, hereditary risk assessment, cancer monitoring, and transplant-related applications.

Natera describes itself as a global leader in cell-free DNA testing dedicated to oncology, women’s health, and organ health. Its platform is especially relevant because cell-free DNA has expanded the clinical use of genetics beyond traditional tissue or germline testing. In prenatal care, oncology, and transplantation, blood-based molecular testing offers a way to monitor biology over time.

The company’s importance comes from its specialization. Rather than operating as a broad reference laboratory, Natera has built a focused molecular platform in high-growth clinical areas where noninvasive testing can change care pathways. Its relevance spans reproductive health, cancer minimal residual disease, therapy monitoring, and donor-derived cell-free DNA testing in transplantation.

Natera’s cell-free DNA expertise, physician adoption, specialty focus, and presence across women’s health, oncology, and organ health support its position among the leading genomics providers globally.

Foundation Medicine

• Headquarters: Cambridge, United States
• Founded: 2010
• Core focus: Oncology comprehensive genomic profiling, companion diagnostics, precision oncology

Foundation Medicine is one of the leading oncology genomics providers globally and a major platform for comprehensive genomic profiling in cancer care. The company focuses on identifying genomic alterations that can help physicians select targeted therapies, immunotherapies, and clinical trial options.

Foundation Medicine reports more than 1.5 million patient comprehensive genomic profiling reports delivered, more than 2,400 research publications, and a large share of approved U.S. companion diagnostic indications for next-generation sequencing testing. Roche’s Foundation Medicine platform also highlights a genomic database of more than 800,000 genomic profiles across more than 150 common and rare tumor subtypes.

The company’s strength lies in oncology-specific clinical evidence and scale. Cancer genomics requires not only sequencing but also interpretation of actionable alterations, therapy associations, resistance mechanisms, and clinical trial relevance. Foundation Medicine’s database and evidence infrastructure give it a strong position in this segment.

Its oncology focus, Roche support, companion diagnostic relevance, and long-standing role in comprehensive genomic profiling support its position as a leading genetic testing and genomics provider in 2023.

Guardant Health

• Headquarters: Palo Alto, United States
• Founded: 2012
• Core focus: Liquid biopsy, cancer genomics, cell-free DNA, early and advanced cancer testing

Guardant Health is one of the leading companies in liquid biopsy and blood-based cancer genomics. Its platform is built around analyzing circulating tumor DNA and related molecular signals to support treatment selection, disease monitoring, and cancer detection.

Guardant360 is positioned as a comprehensive genomic profiling liquid biopsy that helps clinicians identify actionable biomarkers in advanced solid tumors, and Guardant describes its liquid testing as providing genomic and epigenomic insights for cancer care. The company’s European materials emphasize comprehensive genomic profiling through a simple blood draw, reflecting the practical clinical appeal of liquid biopsy.

Guardant’s strength lies in applying genomics to real-world oncology workflows. Tissue biopsy can be difficult, slow, insufficient, or unavailable in some patients. Liquid biopsy offers a complementary or alternative approach for biomarker detection, resistance monitoring, and treatment guidance.

Its liquid biopsy leadership, oncology specialization, payer coverage, clinical adoption, and role in advanced cancer precision medicine support its Tier I position.

---

Tier II — Established Genetic Testing & Genomics Providers

(Alphabetical order)

Ambry Genetics

• Headquarters: Aliso Viejo, United States
• Founded: 1999
• Core focus: Hereditary cancer, rare disease, exome sequencing, inherited conditions

Ambry Genetics is a long-established clinical genetics provider focused on hereditary cancer, rare disease, exome sequencing, and inherited disease testing. The company describes itself as a trusted lab for 25 years, providing accessible genetic testing for hereditary cancer and exome sequencing for rare disease.

Ambry’s relevance lies in its combination of hereditary cancer expertise and broader inherited disease testing. Its patient-facing materials identify current testing categories including hereditary cancer, heart conditions, hereditary neurological disorders, and rare conditions.

The company’s strength is specialist interpretation. Hereditary cancer and rare disease testing require careful variant classification, family-history context, and clinical actionability. Ambry’s long operating history and focused genetics platform support its standing among established genomics providers.

Color Health

• Headquarters: Burlingame, United States
• Founded: 2015
• Core focus: Population genomics, hereditary risk screening, preventive genetics

Color Health is a population health and genomics provider focused on making genetic testing more accessible and actionable across broader patient populations. The company began with hereditary cancer risk testing and has since expanded into population health implementation, clinical programs, and preventive care infrastructure.

Color’s population genomics materials describe an end-to-end solution for health systems to screen broad populations for CDC Tier 1 genomic conditions, including recruitment, return of results, and genetic counseling. Its company history notes that Color launched its first product in 2015 to help patients understand and act on personal cancer risk, beginning with BRCA1, BRCA2, and additional cancer-risk genes.

Color’s strength lies in implementation. Population genomics is not only a laboratory problem; it requires recruitment, consent, logistics, results delivery, counseling, follow-up, and health system integration. Color’s model addresses these operational barriers.

Fulgent Genetics

• Headquarters: Temple City, United States
• Founded: 2011
• Core focus: Clinical genetic sequencing, rare disease panels, whole genome sequencing

Fulgent Genetics is a clinical genetic sequencing provider offering broad test menus across inherited disease, rare disease, oncology, pharmacogenomics, and whole genome sequencing. The company describes itself as an accredited leader in clinical diagnostic genetic sequencing.

Fulgent reports a broad catalog that includes more than 18,000 single-gene tests, more than 900 rare disease tests, whole genome sequencing, whole genome copy-number variation analysis, mitochondrial sequencing, and CLIA/CAP sequencing services. It also highlights Rapid FulGenome as a whole-genome sequencing solution for critically ill patients, analyzing more than 20,000 genes.

The company’s relevance lies in breadth and flexibility. Genetic testing often requires tailored panels, single-gene analysis, exome sequencing, genome sequencing, and copy-number detection depending on the clinical case. Fulgent’s large menu and sequencing infrastructure make it an important established provider.

GeneDx

• Headquarters: Gaithersburg, United States
• Founded: 2000
• Core focus: Rare disease diagnosis, exome sequencing, genome sequencing, pediatric genetics

GeneDx is one of the most important rare disease genomics providers, with a strong focus on whole exome sequencing, whole genome sequencing, neurodevelopmental disorders, pediatric critical care, epilepsy, autism, cerebral palsy, and inherited conditions. The company states that it provides advanced genetic testing to help diagnose rare and inherited conditions through whole exome and genome sequencing.

GeneDx’s provider materials describe genomic sequencing as analysis of large portions of DNA to identify disease-causing variants, with clinical genomic sequencing including whole exome and whole genome sequencing. Its rare disease testing materials emphasize expert variant interpretation and reanalysis, supported by a large rare disease dataset with millions of genetic tests and phenotype data points.

GeneDx is particularly relevant because rare disease diagnosis requires both sequencing depth and interpretive expertise. Many patients undergo long diagnostic odysseys; providers that combine genomic sequencing with phenotype-linked interpretation can materially influence diagnosis and care planning.

Myriad Genetics

• Headquarters: Salt Lake City, United States
• Founded: 1991
• Core focus: Hereditary cancer, prenatal testing, oncology, mental health pharmacogenomics

Myriad Genetics is one of the most established names in clinical genetic testing, with a long history in hereditary cancer testing and broader offerings across prenatal, oncology, and mental health-related genetic testing. The company describes its genetic testing services as supporting detection, treatment, and prevention across hereditary cancer, prenatal, oncology, and mental health applications.

Myriad’s long-standing position in hereditary cancer is especially important. The company states that since launching the first full-length gene sequencing test for hereditary breast cancer in 1996, more than 2 million people have used Myriad hereditary cancer genetic testing.

The company’s strength lies in clinical heritage, physician familiarity, and hereditary risk interpretation. In hereditary cancer, genetic testing must translate variants into prevention, surveillance, risk-reduction, and treatment decisions. Myriad’s brand and evidence base support its position among established providers.

NeoGenomics Laboratories

• Headquarters: Fort Myers, United States
• Founded: 2001
• Core focus: Oncology diagnostics, molecular pathology, cancer genomics

NeoGenomics Laboratories is a major oncology-focused diagnostics and genomics provider. Its platform includes molecular testing, next-generation sequencing, cytogenetics, flow cytometry, immunohistochemistry, pathology, and clinical trial services for oncology.

NeoGenomics is relevant because cancer genomics increasingly depends on specialist laboratories that can integrate pathology, biomarker testing, and genomic profiling. Oncology testing is more complex than simple sequencing; it often requires coordination between tissue pathology, molecular alterations, tumor type, therapeutic context, and clinical trial relevance.

The company’s position in oncology diagnostics gives it an important role in precision medicine, especially for community oncology practices, hospitals, pathologists, and biopharmaceutical partners. Its specialist focus supports its inclusion among established genetic testing and genomics providers.

Quest Diagnostics Genetics

• Headquarters: Secaucus, United States
• Founded: 1967
• Core focus: Broad clinical genetics, reference laboratory testing, genomic infrastructure

Quest Diagnostics is one of the largest clinical laboratory providers in the United States and an important platform for genetic testing. Its genetics services cover a broad range of clinical use cases, including inherited disease, reproductive health, oncology, pharmacogenomics, and specialty testing.

Quest emphasizes the importance of genetic testing in precision medicine and describes a portfolio intended to help providers navigate emerging testing options. Its genomic infrastructure services include molecular genetic solutions for labs or clinics, with disease-state and specialty-based genomic testing from a menu of more than 700 orderable genetic tests.

Quest’s strength lies in scale, access, and integration with routine care. Many patients and physicians encounter genetic testing through large laboratory networks. Quest’s ordering systems, payer relationships, specimen collection infrastructure, and reference lab capabilities make it an important established provider.

Tempus AI

• Headquarters: Chicago, United States
• Founded: 2015
• Core focus: AI-powered precision medicine, oncology genomics, clinical and molecular data

Tempus AI is a precision medicine and genomics company combining molecular testing, clinical data, artificial intelligence, and life sciences partnerships. The company states that it has built one of the world’s largest libraries of clinical and molecular data and an operating system to make that data useful, beginning with cancer.

Tempus’ relevance lies in its data-driven model. Rather than functioning only as a genetic testing laboratory, Tempus connects genomic testing, clinical records, treatment patterns, outcomes, and AI-supported analytics. This is increasingly important as precision medicine depends on linking molecular findings to real-world clinical context.

The company has also expanded beyond oncology into areas such as neuropsychiatry, cardiology, infectious disease, and radiology, while forming a joint venture with SoftBank to provide precision medicine services in Japan. Its AI orientation, data infrastructure, and oncology genomics platform support its position among established providers.

Veracyte

• Headquarters: South San Francisco, United States
• Founded: 2008
• Core focus: Genomic diagnostics, cancer and pulmonary disease classifiers, molecular testing

Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.

The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.

Veracyte’s focused test portfolio, clinical utility orientation, and role in specialty decision-making support its inclusion among established genetic testing and genomics providers.

23andMe / Lemonaid Health Clinical Genetics Platform

• Headquarters: Sunnyvale, United States
• Founded: 2006
• Core focus: Consumer genetics, health-risk reports, pharmacogenetics, personal genomics

23andMe is one of the most recognizable personal genomics brands and remains relevant to the broader genetic testing sector because it helped mainstream consumer access to genetic information. While consumer ancestry and trait testing are outside the core clinical focus of this ranking, 23andMe’s health reports, pharmacogenetic insights, research database, and telehealth-adjacent infrastructure give it a distinctive position.

Its relevance is not equivalent to hospital-integrated clinical genetic testing providers, and its role is therefore placed in Tier II rather than Tier I. However, the company’s scale, brand recognition, consumer genetic database, and public familiarity with DNA-based health insights make it an important participant in the genomics ecosystem.

The platform represents the consumer-facing side of genomics: personal risk awareness, patient engagement, research participation, and broader public normalization of genetic testing.

---

Tier III — Specialist Genetic Testing & Genomics Providers

(Alphabetical order)

• BGI Genomics
• Caris Life Sciences
• Centogene
• Freenome
• SOPHiA GENETICS

---

Remarks

Genetic testing and genomics providers continue to reshape healthcare by enabling molecular diagnosis, hereditary risk assessment, reproductive decision-making, cancer treatment selection, rare disease identification, and population-level prevention. The sector is increasingly defined by the ability to translate DNA, RNA, epigenomic, and clinical data into medically actionable insight.

The organizations recognized in this ranking represent providers whose genomics platforms maintain sustained relevance across clinical genetics, oncology profiling, reproductive health, rare disease sequencing, population genomics, liquid biopsy, and precision medicine data infrastructure. Tier classification reflects relative institutional positioning within the genetic testing and genomics provider sector rather than direct clinical quality rankings.

Tier classification reflects relative clinical scale, test menu breadth, interpretive capability, data infrastructure, reimbursement access, physician adoption, specialty depth, and long-term platform resilience. The ranking does not constitute a medical recommendation, patient referral guidance, investment recommendation, or evaluation of individual genetic counselors, laboratory directors, pathologists, or physicians.

---

Recognition

Organizations included in the Top 20 Genetic Testing & Genomics Providers 2023 ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• institutional presentations
• academic and recruitment materials

Licensing inquiries:
[email protected]